» Articles » PMID: 12446585

Estrogen Receptor Alpha and Activating Protein-1 Mediate Estrogen Responsiveness of the Progesterone Receptor Gene in MCF-7 Breast Cancer Cells

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2002 Nov 26
PMID 12446585
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

The progesterone receptor (PR) gene is activated by estrogen in MCF-7 human breast cancer cells. Although the human PR gene does not contain an estrogen response element (ERE), we have identified a putative activating protein-1 (AP-1) site at +90 in the PR gene that was hypersensitive to deoxyribonuclease I cleavage in genomic Southern analysis, bound purified Fos and Jun, formed a complex with Fos/Jun heterodimers present in MCF-7 nuclear extracts in gel mobility shift assays, and functioned as an estrogen-responsive enhancer in transient cotransfection assays. When the +90 AP-1 site was mutated in the context of the PR gene, estrogen responsiveness was significantly decreased. Purified estrogen receptor (ER) enhanced binding of Fos and Jun to the +90 AP-1 site and bound to an adjacent imperfect ERE half-site. Mutating this ERE half-site diminished the binding of ER, Fos, and Jun and decreased transcription. Chromatin immunoprecipitation assays demonstrated that the ER, Fos, and Jun were present at the +90 AP-1 site in the endogenous PR gene only after treatment of MCF-7 cells with estrogen. These studies suggest that the cooperative interaction of the ER with Fos and Jun proteins helps confer estrogen responsiveness to the endogenous PR gene.

Citing Articles

Hormone Signaling in Breast Development and Cancer.

Agnoletto A, Brisken C Adv Exp Med Biol. 2025; 1464():279-307.

PMID: 39821031 DOI: 10.1007/978-3-031-70875-6_15.


ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation.

Huggins R, Greene G NPJ Breast Cancer. 2023; 9(1):96.

PMID: 38036546 PMC: 10689488. DOI: 10.1038/s41523-023-00601-7.


International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.

Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.

PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.


Assessment of Zearalenone-Induced Cell Survival and of Global Gene Regulation in Mouse TM4 Sertoli Cells.

Savard C, Gawhary S, Boyer A, Chorfi Y Toxins (Basel). 2022; 14(2).

PMID: 35202126 PMC: 8874968. DOI: 10.3390/toxins14020098.


Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2- Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2- Breast Cancer.

Rosswag S, Cotarelo C, Pantel K, Riethdorf S, Sleeman J, Schmidt M Cancers (Basel). 2021; 13(8).

PMID: 33920089 PMC: 8070196. DOI: 10.3390/cancers13081810.